Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Signs Coverage Agreement With Blue Cross Blue Shield of Minnesota

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield (BCBS) of Minnesota to provide access to its cancer diagnostics and genomic testing services to the healthcare network's 2.6 million members.

BCBS Minnesota is the largest health plan in the state, the company said in a statement.

The company signed several similar coverage agreements in 2015 with various insurance providers, including BCBS Illinois in September to cover 7.3 million people, and with with BCBS North Carolina, BCBS Nebraska, and WellMark in November to cover a total of 6.7 million people. CGI said it now has contracts with 29 payers covering 180 million lives across commercial Medicare advantage and Medicaid plans.

"We are looking forward to offering our comprehensive portfolio of oncology diagnostic tests to help Minnesotans have the most effective and high-quality personalized cancer care available," Randy Goodman, Cancer Genetics' director of reimbursement and clinical revenue cycle management, said in a statement."

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.